Literature DB >> 2645710

A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatient renal transplant recipients.

T J Schroeder1, M E Brunson, A J Pesce, L L Hindenlang, P A Mauser, D I Ruckrigl, M L Weibel, G Wadih, M R First.   

Abstract

Rapid and precise cyclosporine measurements are necessary to maximize immunosuppression and minimize toxicity. The new cyclosporine and metabolites TDx fluorescent polarization immunoassay was studied to determine its precision, sensitivity, and stability. Further, it was compared with the existing radioimmunoassay and high-performance liquid chromatography assays for clinical utility. The TDx procedure utilizes 50 microliter of serum or blood. The range of the assay is 0-1000 ng/ml for serum and 0-2000 ng/ml for whole blood. Precision studies of three control levels provided coefficients of variation of 2.1-5.8% for both assays. The sensitivities of the assays were less than 25 ng/ml for serum and less than 50 ng/ml for whole blood. In order to compare the TDx with the currently used RIA and HPLC methods, 362 simultaneous whole blood and serum samples were obtained from 122 renal transplant recipients over a 4-month period. The serum and whole blood TDx assays excluded fewer patients than either the RIA or HPLC assays with regard to sensitivity. The mean serum cyclosporine concentration for samples above the sensitivity was as follows: TDx 120 +/- 5 ng/ml, RIA 116 +/- 4 ng/ml, and HPLC 100 +/- 5 ng/ml. The mean whole-blood cyclosporine concentration for samples above the sensitivity was as follows: TDx 585 +/- 19 ng/ml, RIA 543 +/- 14 ng/ml, and HPLC 178 +/- 5 ng/ml. Serum and blood TDx levels correlated well with RIA levels, with regression coefficients of r = 0.813 and r = 0.897, respectively. Serum and blood TDx levels did not correlate strongly with HPLC levels, with regression coefficients of 0.332 and 0.781, respectively. Seventeen patients were diagnosed as having acute cyclosporine nephrotoxicity. The serum and whole-blood cyclosporine concentrations in these patients were at the upper end of the therapeutic range for all analytical methods. Five patients had acute cellular rejection; serum and whole-blood cyclosporine levels in these patients did not differ significantly from the stable patients when measured by each of the analytical methods. In conclusion, the TDx cyclosporine and metabolites assay provides reliable blood and serum concentrations that correlate well with RIA measurements in renal transplant recipients. This assay offers rapid sample turn-around times making possible same-day results for all patients without putting great demands upon the laboratory.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645710     DOI: 10.1097/00007890-198902000-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

Authors:  L Mieles; R D Gordon; D Mintz; R M Toussaint; O Imventarza; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Acute tubular necrosis following high-dose cyclosporine A therapy.

Authors:  P Shechter
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

4.  The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis.

Authors:  D M Chang; S F Chiao
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

5.  Efficacy of a single pretransplant donor-specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype-mismatched living related donor kidney transplant.

Authors:  C B Davies; J W Alexander; B R Cofer; M R First; T J Schroeder
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

6.  Importance of endogenous prostaglandins for the toxicity of cyclosporin A to rat endocrine and exocrine pancreas?

Authors:  M Rünzi; B M Peskar; J von Schönfeld; M K Müller
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

Review 7.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

8.  In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS.

Authors:  C Pham-Huy; N Sadeg; T Becue; C Martin; G Mahuzier; J M Warnet; M Hamon; J R Claude
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

Review 9.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.